West Pharmaceutical Services (WST) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales were $746.9 million, nearly flat year-over-year, with organic net sales down 0.5%.

• Adjusted and reported diluted EPS for Q3 2024 was $1.85, down from $2.14 and $2.16, respectively, in Q3 2023.

• Gross profit and operating profit both declined year-over-year, primarily due to lower sales volume and an unfavorable product mix.

• The company maintains a leading position in biologics and injectables, with high participation in new drug launches and ongoing investments in capacity and automation.

• Share repurchases increased significantly, with $506.5 million spent year-to-date, reducing cash and cash equivalents.

Financial highlights

• Q3 2024 consolidated gross profit was $264.7 million (35.4% margin), down from $288.3 million (38.6%) in Q3 2023.

• Adjusted operating profit margin was 21.5%, down from 24.2% in Q3 2023.

• Net income for Q3 2024 was $136.0 million, down from $161.3 million in Q3 2023.

• Operating cash flow for the nine months ended September 2024 was $463.3 million, down 13.8% from the prior year.

• Free cash flow for the first nine months of 2024 was $191.2 million, down 32.7% year-over-year.

Outlook and guidance

• Full-year 2024 net sales guidance raised to $2.875–$2.905 billion, reflecting FX impact.

• Adjusted diluted EPS guidance increased to $6.55–$6.75, including a $0.02 FX headwind and $0.26 from stock-based compensation tax benefits.

• Organic net sales expected to decline 1.5%–2% for the year.

• CapEx guidance remains at $375 million for 2024.

• Management expects cash on hand, operations, and credit facility availability to be adequate for foreseeable liquidity needs.